Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

被引:7
|
作者
Nie, Jing [1 ]
Wu, Huina [1 ]
Sun, Lei [1 ]
Ding, Yanjiao [1 ]
Luan, Yepeng [2 ]
Wu, Jiyong [1 ]
机构
[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China
关键词
fuzuloparib; niraparib; olaparib; cost-effectiveness; maintenance treatment; ovarian cancer; BRCA1/2; mutation; THERAPY; CANCER; TRIALS;
D O I
10.3389/fphar.2022.987337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveillance (RS), niraparib and olaparib for platinum-sensitive recurrent OC from the Chinese healthcare systems.Method: A partitioned survival model with three-state (progression-free, progressed, death) was constructed utilizing TreeAge Pro 2011 software to evaluate the economic value of fuzuloparib, niraparib and olaparib maintenance treatment for platinum-sensitive recurrent OC based on the clinical data derived from FZOCUS-2, ENGOT-OV16/NOVA and ENGOT-Ov21/SOLO2. Transition probabilities were estimated from the reported survival probabilities in those trials. Cost and health preference data were derived from the literature. The quality-adjusted life-years (QALYs) and lifetime costs were measured for this analysis. A 5 years horizon and 5%/year discount rates were used. One-way analysis, and probabilistic sensitivity analysis (PSA) were performed to explore the model uncertainties.Results: Total cost of fuzuloparib, niraparib and olaparib were $31628.10, $48183.48 and $54605.54, whereas they had an incremental cost-utility ratio of $31992.69, $32216.08 and $23359.26 per additional progression-free survival (PFS) QALYs gained compared with RS, relatively. Model showed that maintenance fuzuloparib achieved at least an 85.5% probability of CE at the threshold of $37654.50/QALY. One-way sensitivity analysis revealed that the results were sensitive to the PFS and the price of medicines.Conclusion: Fuzuloparib was less cost-effective for patients with germline BRCA1/2 mutation and platinum-sensitive recurrent OC compared to olaparib, but was superior to niraparib from the Chinese healthcare systems perspective.
引用
收藏
页数:8
相关论文
共 36 条
  • [31] Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service
    Armeni, Patrizio
    Borsoi, Ludovica
    Fornaro, Giulia
    Jommi, Claudio
    Colombo, Nicoletta
    Costa, Francesco
    CLINICAL THERAPEUTICS, 2020, 42 (07) : 1192 - +
  • [32] Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
    Tjokrowidjaja, Angelina
    Lee, Chee K.
    Friedlander, Michael
    Gebski, Val
    Gladieff, Laurence
    Ledermann, Jonathan
    Penson, Richard
    Oza, Amit
    Korach, Jacob
    Huzarski, Tomasz
    Manso, Luis
    Pisano, Carmela
    Asher, Rebecca
    Lord, Sarah J.
    Kim, Se Ik
    Lee, Jung-Yun
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Fujiwara, Keiichi
    Sonke, Gabe
    Vergote, Ignace
    Kim, Jae-Weon
    Pujade-Lauraine, Eric
    EUROPEAN JOURNAL OF CANCER, 2020, 139 : 59 - 67
  • [33] Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden
    Polyzoi, Maria
    Ekman, Mattias
    Reithmeier, Anja
    Jacob, Johanna
    Karlsson, Emma
    Bertranou, Evelina
    Linderholm, Barbro
    Hettle, Robert
    PHARMACOECONOMICS-OPEN, 2024, 8 (02) : 277 - 289
  • [34] Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
    Friedlander, Michael
    Gebski, Val
    Gibbs, Emma
    Davies, Lucy
    Bloomfield, Ralph
    Hilpert, Felix
    Wenzel, Lari B.
    Eek, Daniel
    Rodrigues, Manuel
    Clamp, Andrew
    Penson, Richard T.
    Provencher, Diane
    Korach, Jacob
    Huzarski, Tomasz
    Vidal, Laura
    Salutari, Vanda
    Scott, Clare
    Nicoletto, Maria Ornella
    Tamura, Kenji
    Espinoza, David
    Joly, Florence
    Pujade-Lauraine, Eric
    LANCET ONCOLOGY, 2018, 19 (08) : 1126 - 1134
  • [35] A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
    Coleman, Robert L.
    Sill, Michael W.
    Bell-McGuinn, Katherine
    Aghajanian, Carol
    Gray, Heidi J.
    Tewari, Krishnansu S.
    Rubin, Steven C.
    Rutherford, Thomas J.
    Chan, John K.
    Chen, Alice
    Swisher, Elizabeth M.
    GYNECOLOGIC ONCOLOGY, 2015, 137 (03) : 386 - 391
  • [36] Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Tappenden, Paul
    Harnan, Sue
    Ren, Shijie
    Thokala, Praveen
    Wong, Ruth
    Mukuria, Clara
    Green, Clare
    Pledge, Simon
    Tidy, John
    PHARMACOECONOMICS, 2017, 35 (01) : 97 - 109